Champions Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023
December 12, 2023 at 04:15 pm EST
Share
Champions Oncology, Inc. reported earnings results for the second quarter and six months ended October 31, 2023. For the second quarter, the company reported net loss was USD 2.07 million compared to USD 0.016 million a year ago. Basic loss per share from continuing operations was USD 0.15. Diluted loss per share from continuing operations was USD 0.15.
For the six months, net loss was USD 4.64 million compared to USD 0.335 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.02 a year ago. Diluted loss per share from continuing operations was USD 0.34 compared to USD 0.02 a year ago.
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Companyâs TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.
CHAMPIONS ONCOLOGY, INC. 
